Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design-Reference-Cited by-同舟云学术

Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design

Published:2015-06 Issue:3 Volume:13 Page:250-256
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Sonpavde Guru,Pond Gregory R.,Mullane Stephanie,Qu Angela Q.,Di Lorenzo Giuseppe,Federico Piera,Necchi Andrea,Rosenberg Jonathan E.,Bellmunt Joaquim,Choueiri Toni K.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium;Sonpavde;Lancet Oncol,2010

2. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer;Choueiri;J Clin Oncol,2012

4. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study;Ko;Lancet Oncol,2013

5. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia;Wani;J Am Chem Soc,1971

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC );International Journal of Cancer;2020-05-07

2. Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study;In Vivo;2019

3. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study;Cancer Chemotherapy and Pharmacology;2017-07-20

4. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma;European Urology;2016-04

5. Docetaxel for the treatment of bladder cancer;Expert Opinion on Investigational Drugs;2015-11-04